BLRX

BioLineRx Ltd.

Nasdaq · Pharmaceutical Preparations · Inc. L3 · CIK 0001498403

$3.37 -2.88% $14.7M

High Impact Filing (7/10)

Vol

Market Cap$14.7M

Cap SizeNano Cap

Inst. Holders7 funds

Inst. Value$37.3K

Inst. Activity0 buys / 1 sells

Reddit Sentiment33° Cool

SEC Reports5

Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. L3·CIK 0001498403·Prev Close $3.47

Recent Activity

May 27, 2026 SEC

BioLineRx reported Q1 2026 results: royalty revenues of $0.5M (up from $0.3M YoY) but operating loss widened to $3.0M fr

6-K — Impact 5/10

May 22, 2026 SEC

BioLineRx and partner Hemispherian AS announced that two preclinical abstracts on GLIX1, a first-in-class oral TET2 acti

6-K — Impact 6/10

May 19, 2026 SEC

BioLineRx announced new preclinical GLIX1 data showing potent anti-tumor activity in glioblastoma (GBM) models, includin

6-K — Impact 5/10

Inst.

RHUMBLINE ADVISERS — TRIM

2,353 shares ($5.4K)

Inst.

MORGAN STANLEY — NEAR_EXIT

100 shares ($277.00)

Price Targets

Historical data — last covering-analyst action Jun 2025. No current recommendation available.

$17.50 (Jun 2025)

Current $3.37 Low $12.00 Median $17.50 High $23.00 2 analysts

$12.00 $23.00

Analyst Ratings

Historical Analyst Actions

Date	Firm	Action	Rating
Jun 17, 2025	HC Wainwright & Co.	REITERATE	Buy → Buy
May 30, 2025	Jones Trading	UPGRADE	Hold → Buy
May 28, 2025	HC Wainwright & Co.	REITERATE	Buy → Buy
Apr 2, 2025	Jones Trading	DOWNGRADE	Buy → Hold
Mar 31, 2025	HC Wainwright & Co.	MAINTAIN	Buy → Buy

Earnings Estimates

Period	EPS Est.	Range	Growth	#
Current Q	$-0.30 ▲ +6.3%	$-0.30 — $-0.30	0% YoY	1
Next Q	$-0.18 ▲ +5.3%	$-0.18 — $-0.18	0% YoY	1
Current FY	$-0.93 ▲ +14.7%	$-0.93 — $-0.93	0% YoY	1
Next FY	$-0.64 ▲ +4.5%	$-0.64 — $-0.64	31% YoY	1

Latest Reports

MIXED 6-K 5/10

BioLineRx reported Q1 2026 results: royalty revenues of $0.5M (up from $0.3M YoY) but operating loss widened to $3.0M fr

May 27, 2026

BULLISH 6-K 6/10

BioLineRx and partner Hemispherian AS announced that two preclinical abstracts on GLIX1, a first-in-class oral TET2 acti

May 22, 2026

Top Institutional Holders

Fund	Value	Move
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$23.6K	—
RHUMBLINE ADVISERS	$5.4K	TRIM
WELLS FARGO & COMPANY/MN	$4.0K	TRIM
CITIGROUP INC	$4.0K	—
MORGAN STANLEY	$230.00	NEAR_EXIT

Reddit Sentiment

33°

Cool

Bearish Neutral Bullish

2 mentions 0 bullish 2 bearish

7 institutional holders with $37.3K total value (16,145 shares) as of 2026-Q1. Top holders: SUSQUEHANNA, RHUMBLINE, WELLS. Net selling activity: 1 institutions trimmed/exited vs 0 added.

Top Institutional Holders — 2026-Q1

#	Fund	Shares	Value	% of Tracked	Last Move
1	SUSQUEHANNA INTERNATIONAL GROUP, LLP	10,200	$23.6K	63.2%	—
2	RHUMBLINE ADVISERS	2,353	$5.4K	14.6%	TRIM -29.8%
3	WELLS FARGO & COMPANY/MN	1,750	$4.0K	10.8%	TRIM -41.7%
4	CITIGROUP INC	1,728	$4.0K	10.7%	—
5	MORGAN STANLEY	100	$230.00	0.6%	NEAR_EXIT -98.3%
6	Rockefeller Capital Management L.P.	12	$28.00	0.1%	—
7	DANSKE BANK A/S	2	$5.00	0.0%	—

Recent Position Changes

Fund	Action	Prev Shares	Curr Shares	Change %	Value	Quarter
RHUMBLINE ADVISERS	TRIM	3,353	2,353	-29.8%	$5.4K	2026-Q1
MORGAN STANLEY	NEAR_EXIT	5,953	100	-98.3%	$277.00	2025-Q4
BANK OF AMERICA CORP /DE/	DOUBLED	2	10	+400.0%	$28.00	2025-Q4
CITADEL ADVISORS LLC	TRIM	14,954	10,020	-33.0%	$37.9K	2025-Q3
MORGAN STANLEY	DOUBLED	1,543	5,953	+285.8%	$22.5K	2025-Q3
RHUMBLINE ADVISERS	TRIM	4,275	3,070	-28.2%	$11.6K	2025-Q3
RHUMBLINE ADVISERS	DOUBLED	1,530	4,275	+179.4%	$19.5K	2025-Q2
WELLS FARGO & COMPANY/MN	TRIM	3,000	1,750	-41.7%	$8.0K	2025-Q2
MORGAN STANLEY	TRIM	197,537	79,102	-60.0%	$16.9K	2024-Q4
RHUMBLINE ADVISERS	ADD	32,611	42,961	+31.7%	$9.1K	2024-Q4
UBS Group AG	DOUBLED	984	9,196	+834.6%	$2.0K	2024-Q4
WELLS FARGO & COMPANY/MN	NEAR_EXIT	35,035	5,535	-84.2%	$1.2K	2024-Q4
Alyeska Investment Group, L.P.	TRIM	1,953,366	866,495	-55.6%	$464.5K	2024-Q3
MORGAN STANLEY	DOUBLED	68,437	197,537	+188.6%	$105.9K	2024-Q3
Atria Investments, Inc	ADD	104,781	133,974	+27.9%	$71.8K	2024-Q3
RHUMBLINE ADVISERS	ADD	25,741	32,611	+26.7%	$17.5K	2024-Q3

∅

No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.

5 SEC filing reports analyzed. Sentiment: 3 bullish, 0 bearish, 1 mixed, 1 neutral. Avg impact: 5.2/10.

MIXED 6-K 5/10

BioLineRx reported Q1 2026 results: royalty revenues of $0.5M (up from $0.3M YoY) but operating loss

May 27, 2026

BULLISH 6-K 6/10

BioLineRx and partner Hemispherian AS announced that two preclinical abstracts on GLIX1, a first-in-

May 22, 2026

BULLISH 6-K 5/10

BioLineRx announced new preclinical GLIX1 data showing potent anti-tumor activity in glioblastoma (G

May 19, 2026

NEUTRAL 3 3/10

Philip A. Serlin, CEO of BioLineRx Ltd., filed a Form 3 disclosing his beneficial ownership of emplo

Mar 27, 2026

BULLISH 6-K 7/10

BioLineRx has initiated a Phase 1/2a clinical trial for GLIX1, a first-in-class oral small molecule

Mar 26, 2026

∅

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Analyst Price Targets

Historical data — last covering-analyst action Jun 2025. No current recommendation available.

$17.50 mean target (Jun 2025)

$12.00 Low $23.00 High

Metric	Value
Current Price	$3.37
Target Low	$12.00
Target Mean	$17.50
Target Median	$17.50
Target High	$23.00
# Analysts	2
Recommendation	— (no recent coverage)

Earnings Estimates & Revisions

Period	EPS Avg	EPS Low	EPS High	EPS Growth	30d Rev.	Up/Down	Rev. Avg	Rev. Growth	Analysts
Current Q 2026-06-30	$-0.30	$-0.30	$-0.30	0.0%	+6.3%	1↑ 0↓	$0.0B	40.9%	1
Next Q 2026-09-30	$-0.18	$-0.18	$-0.18	0.0%	+5.3%	1↑ 0↓	$0.0B	-11.9%	1
Current FY 2026-12-31	$-0.93	$-0.93	$-0.93	0.0%	+14.7%	1↑ 0↓	$0.0B	51.2%	1
Next FY 2027-12-31	$-0.64	$-0.64	$-0.64	31.2%	+4.5%	1↑ 0↓	$0.0B	12.6%	1

Current Quarter EPS Revision History

Timepoint	EPS Estimate	Change
Current	$-0.300
7d ago	$-0.320	+0.020
30d ago	$-0.320	+0.020
60d ago	$-0.320	+0.020
90d ago	$-0.270	-0.030

7 analyst firms have rated this stock: 2 upgrades, 2 downgrades, 4 initiations.

Historical Analyst Actions

Date	Analyst Firm	Action	Previous Rating	New Rating
Jun 17, 2025	HC Wainwright & Co.	REITERATE	Buy	Buy
May 30, 2025	Jones Trading	UPGRADE	Hold	Buy
May 28, 2025	HC Wainwright & Co.	REITERATE	Buy	Buy
Apr 2, 2025	Jones Trading	DOWNGRADE	Buy	Hold
Mar 31, 2025	HC Wainwright & Co.	MAINTAIN	Buy	Buy
Nov 25, 2024	HC Wainwright & Co.	MAINTAIN	Buy	Buy
Nov 6, 2024	HC Wainwright & Co.	REITERATE	Buy	Buy
Jun 3, 2024	HC Wainwright & Co.	REITERATE	Buy	Buy
May 29, 2024	HC Wainwright & Co.	REITERATE	Buy	Buy
Apr 17, 2024	HC Wainwright & Co.	REITERATE	Buy	Buy
Mar 26, 2024	HC Wainwright & Co.	REITERATE	Buy	Buy
Feb 29, 2024	HC Wainwright & Co.	REITERATE	Buy	Buy
Nov 20, 2023	HC Wainwright & Co.	REITERATE	Buy	Buy
Sep 15, 2023	HC Wainwright & Co.	MAINTAIN	Buy	Buy
Aug 31, 2023	HC Wainwright & Co.	REITERATE	Buy	Buy
May 25, 2023	Oppenheimer	REITERATE	—	Outperform
Feb 23, 2021	HC Wainwright & Co.	MAINTAIN	—	Buy
Dec 16, 2020	HC Wainwright & Co.	MAINTAIN	—	Buy
Aug 4, 2017	Oppenheimer	INITIATE	—	Outperform
May 18, 2017	Maxim Group	UPGRADE	Hold	Buy
Feb 13, 2017	Rodman & Renshaw	INITIATE	—	Buy
Aug 12, 2016	Maxim Group	DOWNGRADE	Buy	Hold
Mar 9, 2016	JMP Securities	MAINTAIN	—	Market Outperform
Jun 22, 2015	JMP Securities	INITIATE	—	Outperform
Jun 22, 2015	JP Morgan	INITIATE	—	Market Outperform

∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

33°

Cool

Bearish Neutral Bullish

2 mentions 0 bullish 2 bearish 2 time periods

Reddit Sentiment History

Date	Mentions	Sentiment	Bullish	Bearish	Threads
May 27, 2026	1	40° Cool	0	1	1
May 27, 2026	1	40° Cool	0	1	1

Recent Reddit Threads

r/pennystocks Bearish 16d 21h ago

BLRX Achieves Key Milestones in Clinical Development and Revenue Growth.

▲ 1 💬 1 ⚡ 0.5

r/pennystocks Bullish 22d 1h ago

BioLineRx (BLRX) and Hemispherian Showcase New GLIX1 Data Ahead of ASCO 2026 as First-in-Human GBM Trial Enrolls

▲ 1 💬 1 ⚡ 0.5

Apr 1, 2026

Clinical Trial

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

Phase Phase 3 — TERMINATED